Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TLR4 | O00206 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31641122 | 0.88 | ALDH1A1 (0.58) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL23857689 | 0.88 | TSHR (0.59) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL23857687 | 0.88 | TSHR (0.59) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL16512974 | 0.87 | ALDH1A1 (0.60) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL21945751 | 0.84 | ALDH1A1 (0.60) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL21946019 | 0.84 | ALDH1A1 (0.60) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL21945750 | 0.84 | ALDH1A1 (0.60) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL10196993 | 0.84 | ALDH1A1 (0.60) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL10167705 | 0.84 | ALDH1A1 (0.60) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL361720 | 0.83 | ALDH1A1 (0.62) | ALDH1A1GAATSHREPHX1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698530-A1 | NK3 MODULATORS AND USES THEREOF | Kallyope, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12281114-B2 | NK3 modulators and uses thereof | KALLYOPE, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| WO-2024220539-A1 | NK3 MODULATORS AND USES THEREOF | KALLYOPE, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| EP-2683722-A1 | FLUOROPHENYL BICYCLIC HETEROARYL COMPOUNDS | Novartis AG (CH) | 2014-01-15 | — | — | EP | disclosed |
| US-20130338152-A1 | FLUOROPHENYL BICYCLIC HETEROARYL COMPOUNDS | IRM LLC (BM) | 2013-12-19 | — | — | US | disclosed |
| US-20120289501-A1 | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls | NOVARTIS AG (CH) | 2012-11-15 | — | — | US | disclosed |
| EP-2504339-A1 | BENZENE-FUSED 6-MEMBERED OXYGEN-CONTAINING HETEROCYCLIC DERIVATIVES OF BICYCLIC HETEROARYLS | Novartis AG (CH) | 2012-10-03 | — | — | EP | disclosed |
| WO-2012120469-A1 | FLUOROPHENYL BICYCLIC HETEROARYL COMPOUNDS | NOVARTIS AG (CH) | 2012-09-13 | — | — | WO | disclosed |
| EP-2475668-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | Novartis AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| US-20120165310-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| WO-2011064211-A1 | BENZENE-FUSED 6-MEMBERED OXYGEN-CONTAINING HETEROCYCLIC DERIVATIVES OF BICYCLIC HETEROARYLS | NOVARTIS AG (CH) | 2011-06-03 | — | — | WO | disclosed |
| WO-2011029915-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | NOVARTIS AG (CH) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338152-A1 | FLUOROPHENYL BICYCLIC HETEROARYL COMPOUNDS | IGF1R, IGFBP1, IGFBP2 | ALDH1A1 1566/4885GAA 1731/4885TSHR 100/4885 |
| US-20120289501-A1 | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls | CYP1B1, CYP11B2, CCNI | ALDH1A1 385/4885GAA 1035/4885TSHR 3358/4885 |
| US-12281114-B2 | NK3 modulators and uses thereof | TAC3, TACR3, TACR2 | ALDH1A1 4066/4885GAA 1359/4885TSHR 564/4885 |
| US-20120165310-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | ETV6, CYP11B2, CYP11B1 | ALDH1A1 477/4885GAA 891/4885TSHR 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.